Revolution Medicines announced exciting results on three clinical trials evaluating daraxonrasib, their oral RAS inhibitor, that have the potential to transform treatment options for patients with metastatic pancreatic ductal adenocarcinoma […]
Promising results combining immunotherapy and chemotherapy before surgery in pancreatic cancer
A recent study published in Nature Communications, sponsored by the UCLA Health Jonsson Comprehensive Cancer Center, showed that adding immunotherapy to standard chemotherapy, before surgery, may benefit a subset of […]
pNET Treatments and Emerging Research
As an overview of Pancreatic Neuroendocrine Tumors, we look at the current standard treatment for pNETs and what emerging therapies are on the horizon. Also discussed is the translational research […]
Hirshberg Foundation Launches PNET Pathway Grant Program to Accelerate Research
The Hirshberg Foundation for Pancreatic Cancer Research is proud to announce the launch of the PNET Pathway Grant Program, a new research initiative focused on accelerating discoveries in pancreatic neuroendocrine […]
Unraveling Cachexia, Insights from the Hirshberg Symposium at the APA Meeting
Each year at the American Pancreas Association (APA) meeting, the conference opens with the Hirshberg Foundation Symposium. This year’s topic, pancreatic cancer cachexia, highlighted an important condition impacting many pancreatic […]
UCLA Scientists Develop Promising “Off-the-Shelf” CAR-NKT Cell Therapy for Pancreatic Cancer
The Hirshberg Foundation is committed to advancing the most innovative science with the potential to change outcomes for pancreatic cancer patients. UCLA is home to many of the nation’s leading […]